Browsing Tag
AbbVie
78 posts
Oruka Therapeutics stock surges as ORKA-001 psoriasis trial success puts $1.1bn biotech strategy to the test
Oruka Therapeutics stock rallies after ORKA-001 delivers 61% psoriasis clearance. Explore its $1.1B cash position and Phase 3 growth potential.
Genmab targets new oncology growth as Rina-S delivers major survival gains over chemotherapy
Genmab stock jumps 9.5% after Rina-S delivers major ovarian cancer survival gains. Explore its FDA prospects, competition and growth outlook.
Roivant Sciences targets new uveitis market as brepocitinib delivers major clinical breakthrough
Roivant Sciences stock rises after brepocitinib's double Phase 3 uveitis success. Explore its FDA plans, cash strength and growth potential.
Odyssey Therapeutics targets major inflammatory bowel disease opportunity with oral OD-001
Odyssey Therapeutics stock rises on OD-001 ulcerative colitis results. Explore its $433M cash position, clinical trials and growth prospects.
RAPP stock gains on RAP-219 clinical success as Wall Street weighs modest treatment benefit
Rapport Therapeutics' RAP-219 trial lifts RAPP stock as investors weigh its bipolar mania potential. Discover the Phase 3 outlook and market risks.
Ironwood Pharmaceuticals (Nasdaq: IRWD) names Tammi Gaskins CEO as LINZESS profits rise
Ironwood Pharmaceuticals has appointed Chief Commercial Officer Tammi Gaskins to succeed Tom McCourt as Chief Executive Officer from January 2027. The succession follows a major 2025 workforce reduction and arrives after sharply stronger LINZESS economics restored profitability, leaving Gaskins to balance cash generation with the late-stage development of apraglutide.
ADARx Pharmaceuticals jumps in Nasdaq debut after upsized $446.3m IPO
ADARx Pharmaceuticals has completed one of the larger biotechnology flotations of 2026, pricing an upsized $446.3 million Nasdaq offering at the top of its range before shares opened 30% above the IPO price.
Oruka Therapeutics builds long-acting psoriasis case as ORKA-001 clearance deepens without redosing
ORKA-001 reaches 71.4% complete psoriasis clearance without redosing as Oruka Therapeutics advances its long-acting biologic toward Phase 3.
ADARx IPO grows to $446m as RNA drug developer targets Nasdaq debut
ADARx Pharmaceuticals has priced an enlarged U.S. IPO at $17 a share, generating about $446.3 million before expenses, while AbbVie plans a concurrent investment that would give it roughly 4.9% ownership.
Mapi Pharma targets cariprazine lifecycle extension with once-monthly injectable
Mapi’s monthly Cariprazine Depot clears its first safety hurdle as a $3.6bn oral franchise approaches a key 2029 patent transition.